Adjusted age-specific HRs of SBP for mitral regurgitation.

<p>Age bands refer to age at baseline. Adjustments were for sex, BMI, smoking, year of BP measurement, total cholesterol, LDL cholesterol, and HDL cholesterol. Confidence intervals are displayed as floating absolute risks. HRs and 95% CI are displayed for 1 mmHg increments in SBP and plotted using Cox regression with restricted cubic spline with 4 knots, relative to the reference category (individuals aged 30–50 years with usual SBP 115–120 mmHg). Abbreviations: BMI, body mass index; BP, blood pressure; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein; SBP, systolic blood pressure.</p

Subgroup analyses for mitral regurgitation per 20 mmHg higher usual SBP.

<p>Models are adjusted for sex, BMI, smoking, calendar year, total cholesterol, LDL cholesterol, and HDL cholesterol. Valve replacement therapy refers to mitral valve repair or replacement. Confidence intervals are displayed as floating absolute risks. Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein; MR, mitral regurgitation; SBP, systolic blood pressure.</p

Baseline characteristics and outcome rates by categories of usual SBP.

<p>Baseline characteristics and outcome rates by categories of usual SBP.</p

HRs for mitral regurgitation by categories of usual SBP.

<p>HRs and 95% CI are displayed using floating absolute risk and are corrected for regression dilution. Models are adjusted for age, sex, BMI, smoking, calendar year, total cholesterol, LDL cholesterol, and HDL cholesterol. Abbreviations: BMI, body mass index; HDL, high-density lipoprotein; HR, hazard ratio; LDL, low-density lipoprotein; MR, mitral regurgitation; SBP, systolic blood pressure.</p

Adverse events between more intensive and less intensive BP lowering regimen.

<p>Adverse events between more intensive and less intensive BP lowering regimen.</p

Effect of intensive BP lowering on risk of heart failure (a), cardiovascular death (b), and end stage kidney disease (c).

<p>Boxes and horizontal lines represent RR and 95% CI for each trial. Size of boxes is proportional to weight of that trial result. Diamonds represent the 95% CI for pooled estimates of effect and are centered on pooled RR.</p

Univariate meta-regression of intensive blood pressure lowering on major cardiovascular outcomes.

<p>Univariate meta-regression of intensive blood pressure lowering on major cardiovascular outcomes.</p

Characteristics of the studies included.

<p>ADPKD, autosomal dominant polycystic kidney disease; CV, cardiovascular; GFR, glomerular filtration rate; MI, myocardial infarction; NA, not available; NR, not reported.</p

Effects of intensive BP lowering on the risk of major cardiovascular events in subgroups of trials.

<p>Effects of intensive BP lowering on the risk of major cardiovascular events in subgroups of trials.</p

Effect of intensive BP lowering on risk of major cardiovascular events (a), myocardial infarction (b), and stroke (c).

<p>Boxes and horizontal lines represent RR and 95% CI for each trial. Size of boxes is proportional to weight of that trial result. Diamonds represent the 95% CI for pooled estimates of effect and are centered on pooled RR.</p